Characterizing the emergence of amyloid and tau burden in Down syndrome.

ABSTRACT:

Introduction

Almost all individuals with Down syndrome (DS) will develop neuropathological features of Alzheimer's disease (AD). Understanding AD biomarker trajectories is necessary for DS-specific clinical interventions and interpretation of drug-related changes in the disease trajectory.

Methods

A total of 177 adults with DS from the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) underwent positron emission tomography (PET) and MR imaging. Amyloid-beta (Aβ) trajectories were modeled to provide individual-level estimates of Aβ-positive (A+) chronicity, which were compared against longitudinal tau change.

Results

Elevated tau was observed in all NFT regions following A+ and longitudinal tau increased with respect to A+ chronicity. Tau increases in NFT regions

SUBMITTER: Zammit MD 

PROVIDER: S-EPMC10843570 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature